Selina M Luger
Selina M Luger
Current standard of care for consolidation therapy for AML varies based on age and induction regimen, among other factors. Many trials have sought to determine the optimal dose, number of cycles, and schedule for consolidation with cytarabi...
Jacob M Rowe
Jacob M Rowe
There has been remarkable progress in the treatment of acute myeloid leukemia (AML) which has spanned 5 decades. The changing trends have led to new approaches and significant improvement in outcomes. This review has summarized the historic...
Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome [0.03%]
移植前强化诱导化疗或低甲基化药物在骨髓增生异常综合征中应用的现状
Christian Niederwieser,Nicolaus Kröger
Christian Niederwieser
Myelodysplastic syndrome is a heterogeneous disease with survival probabilities ranging from a few months to several years. Allogeneic hematopoietic cell transplantation (HCT) remains the only curative treatment. Although access (up to 75 y...
Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype? [0.03%]
Ph-likeALL是否已经取代Ph+ALL成为最不理想的亚型？
Thai Hoa Tran,Sarah K Tasian
Thai Hoa Tran
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a subset of high-risk B-ALL associated with high relapse risk and inferior clinical outcomes across the pediatric-to-adult age spectrum. Ph-like ALL is characterized...
Jerry L Spivak
Jerry L Spivak
The myeloproliferative neoplasms (MPN), polycythemia vera (PV), essential thrombocytosis and primary myelofibrosis, are an unusual group of myeloid neoplasms, which arise in a pluripotent hematopoietic stem cell (HSC) due to gain of functio...
Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage [0.03%]
通过基因组学重新定义来源不明的白血病的生物基础:BCL11B在来源不明的急性白血病中的异常调节
Lindsey E Montefiori,Charles G Mullighan
Lindsey E Montefiori
Acute leukemias of ambiguous lineage (ALAL), including mixed phenotype acute leukemia (MPAL) and related entities such as early T-cell precursor acute leukemia (ETP-ALL), remain diagnostic and clinical challenges due to limited understandin...
Nirupama Mulherkar,David T Scadden
Nirupama Mulherkar
Acute myeloid leukemia (AML) continues to be associated with relapse and resistance to chemotherapy. The bone marrow microenvironment in AML has been shown to regulate responsiveness to chemotherapy and to support disease progression. This ...
How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)? [0.03%]
克隆性造血对骨髓增生异常综合征(MDS)或急性髓系白血病(AML)发生的预测价值如何？
David P Steensma
David P Steensma
Clonal hematopoiesis (CH) - a biological state in which one or a small number of hematopoietic stem or progenitor cells contribute disproportionately to blood cell production, usually as a result of somatic gene mutations in the stem cells ...
Laura C Michaelis
Laura C Michaelis
The traditional cytotoxic induction regimen for acute myeloid leukemia (AML) is seven days of standard-dose cytarabine and three days of an anthracycline antibiotic (such as daunorubicin or idarubicin), commonly known as "7 + 3." Many studi...
It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS [0.03%]
到了转变骨髓增生异常综合症治疗模式的时间了：重点介绍高风险MDS探索组合疗法的新型发展和当前的研究方法
Luis E Aguirre,Rami Komrokji,Eric Padron
Luis E Aguirre
Higher risk myelodysplastic syndromes are defined as a subset of disease with higher risk of AML transformation and poor overall survival. For decades, therapeutic options for high-risk MDS have been limited to allogeneic stem cell transpla...